Secondly, we developed a CXCR4+ SC EC model to evaluate the percent of the administered dose that reaches the tumor tissue, since the subcutaneous tumor model is more suited than the orthotopic model for this specific purpose. The gene discussed is CXCR4; the disease is neoplasm.